Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Insulet Corporation

PODDNasdaqHealth Care EquipmentUSMid cap
  • S&P 500
  • Russell 1000

What Insulet Corporation is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 30, 2026: $3.05 billion, up 29% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.29 billion, down 28% from a year earlier.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to June 30, 2026: $0.22 billion, up 100% from a year earlier.SEC EDGAR filings (XBRL)
  • Share buybacks in the fiscal year to December 31, 2025: $0.06 billion.SEC EDGAR filings (10-K)
  • Long-term debt issued in the fiscal year to December 31, 2025: $0.44 billion.SEC EDGAR filings (10-K)
  • Latest earnings call or results release (August 5, 2026): sentiment -0.20 on a −1 to +1 scale (negative), confidence 0.60 of 1.Palanor Discourse
  • Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 1 held.Guidance Ledger (8-K results releases)
  • Latest annual report (filed February 18, 2026): 1 risk factor added, 4 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net buyers in Q3 2026: $0.2 million on the open market.SEC Form 4
  • 734 institutional managers reported a position at June 30, 2026 (−55 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 11 (11 a year earlier).U.S. Department of Labor (OFLC)

Company Posture

How Company Posture is measured →

What Insulet Corporation is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.

Expanding · Hedging

Expanding ↔ Retrenching

Expanding

RetrenchingExpanding

Confident ↔ Hedging

Hedging

HedgingConfident

Pressure

Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).

Credit

How these are built →

Insulet Corporation's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.

Debt on the balance sheet

$0.9B

  • Due within a year $0.0B
  • Longer term $0.9B
  • Default point $0.5B (short + ½ long)

Finance leases included · Jun 30, 2026 filing

Bonds priced, last 12 months

None

U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Insulet Corporation: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

$0.29BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Insulet Corporation: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Insulet Corporation: revenue, trailing twelve months

$ billions, from SEC filings

$3.1BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Insulet Corporation: share buybacks by fiscal year

Cash paid to repurchase common stock, $ billions, from the 10-K

$0.06BData to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Insulet Corporation: debt issued and repaid by fiscal year

Long-term debt, $ billions, from the 10-K

Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Insulet Corporation: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Insulet Corporation: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

8.8Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Insulet Corporation: guidance raised minus lowered

Guidance Ledger statements by quarter

1.0Data 23 days ago
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Insulet Corporation: earnings call sentiment

Palanor Discourse score per call, −1 to +1

−0.20Data to Aug 2026
ImageDataPalanor calculation
Business

Insulet Corporation: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.60Data to Aug 2026
ImageDataPalanor calculation
Business

Insulet Corporation: risk factors added per annual report

New Item 1A risk factors in each 10-K

1.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Insulet Corporation: H-1B filings certified

Labor Condition Applications by quarter received

11.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Insulet Corporation: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

$0.2MData 23 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Insulet Corporation: institutional holders

Managers reporting a position on Form 13F, by quarter

734.0Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 20, 2026Lobbying
    Lobbying report (INSULET CORPORATION)third_quarter 2026 · $0.1 million
  2. Oct 20, 2026Patent
    Patent granted: DISPENSING DEVICE FOR WEARABLE DRUG DELIVERY DEVICEUS 12766248
  3. Oct 20, 2026Patent
    Patent granted: TECHNIQUES FOR IMAGE-BASED MONITORING OF BLOOD GLUCOSE STATUSUS 12765808
  4. Oct 19, 2026Lobbying
    Lobbying report (TODD STRATEGY GROUP)third_quarter 2026 · $0.1 million
  5. Oct 13, 2026Patent
    Patent granted: SYSTEMS AND METHODS FOR ENSURING SUFFICIENT BOLUS DOSING FOR MEAL COMPENSATIONUS 12763187
  6. Oct 13, 2026Patent
    Patent granted: FLEXIBLE LINKAGE FOR POSITIVE DISPLACEMENT PUMPSUS 12758705
  7. Oct 13, 2026Patent
    Patent granted: AUTOMATED ARTIFICIAL PANCREAS INSULIN ONBOARDING AND TOTAL DAILY INSULIN DELIVERY ADAPTIVITY BASED ON INSULIN HISTORYUS 12763189
  8. Sep 21, 20268-K
    Material agreement signedItem 1.01
  9. Sep 16, 20268-K
    Director or officer changeItem 5.02
  10. Sep 10, 20268-K
    Director or officer changeItem 5.02
  11. Jul 20, 2026Lobbying
    Lobbying report (INSULET CORPORATION)second_quarter 2026 · $0.2 million
  12. Jul 13, 2026Lobbying
    Lobbying report (TODD STRATEGY GROUP)second_quarter 2026 · $0.1 million
  13. Jun 25, 20268-K
    Director or officer changeItem 5.02
  14. May 21, 20268-K
    Shareholder vote resultsItem 5.07
  15. Apr 20, 2026Lobbying
    Lobbying report (TODD STRATEGY GROUP)first_quarter 2026 · $0.1 million
  16. Apr 20, 2026Lobbying
    Lobbying report (INSULET CORPORATION)first_quarter 2026 · $0.1 million
  17. Mar 4, 20268-K
    Director or officer changeItem 5.02
  18. Feb 24, 20268-K
    Auditor changeItem 4.01
  19. Feb 18, 202610-K
    Annual report (10-K)1 risk factors added, 4 removed
  20. Feb 3, 20268-K
    Material agreement signedItem 1.01
  21. Jan 19, 2026Lobbying
    Lobbying report (INSULET CORPORATION)fourth_quarter 2025 · $0.1 million
  22. Jan 17, 2026Lobbying
    Lobbying report (TODD STRATEGY GROUP)fourth_quarter 2025 · $0.1 million
  23. Dec 19, 20258-K
    Auditor changeItem 4.01
  24. Dec 17, 20258-K
    Director or officer changeItem 5.02
  25. Oct 23, 20258-K
    Director or officer changeItem 5.02
  26. Sep 16, 20258-K
    Director or officer changeItem 5.02
  27. Jun 9, 20258-K
    Material agreement signedItem 1.01
  28. Jun 9, 20258-K
    Material agreement terminatedItem 1.02
  29. May 28, 20258-K
    Director or officer changeItem 5.02
  30. May 28, 20258-K
    Shareholder vote resultsItem 5.07
  31. Apr 28, 20258-K
    Director or officer changeItem 5.02
  32. Apr 9, 20258-K
    Director or officer changeItem 5.02
  33. Mar 21, 20258-K
    Material agreement signedItem 1.01
  34. Mar 17, 20258-K
    Director or officer changeItem 5.02
  35. Mar 10, 20258-K
    Material agreement signedItem 1.01
  36. Feb 21, 20258-K
    Director or officer changeItem 5.02
  37. Feb 21, 202510-K
    Annual report (10-K)3 risk factors added, 2 removed
  38. Feb 23, 202410-K
    Annual report (10-K)1 risk factors added, 1 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Globus Medical GMED$3.1B$0.8BJun 30, 2026
Revvity RVTY$2.9B$0.6BJul 5, 2026
Bruker BRKR$3.5B$0.1BJun 30, 2026
Teleflex TFX$2.3B$0.2BJun 30, 2026
Idexx Laboratories IDXX$4.5B$1.3BJun 30, 2026
Dexcom DXCM$5.0B$1.4BJun 30, 2026
ResMed| RMD$5.7B$1.6BJun 30, 2026
Steris STE$6.0B$0.9BJun 30, 2026

Identity

SEC CIK
1145197
SAM UEI
HUBSA85LEYT7

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.